Fulcrum therapeutics to evaluate losmapimod as potential treatment for covid-19

Fulcrum therapeutics to evaluate losmapimod as potential treatment for covid-19.fulcrum therapeutics - redux4 interim analysis in facioscapulohumeral dystrophy on track for q3 readout.fulcrum therapeutics inc - ftx-6058 phase 1 trial on track for q4 2020 initiation.fulcrum therapeutics inc - investigational new drug application submitted for losmapimod.fulcrum therapeutics- preparing to start phase 3 trial for losmapimod.fulcrum therapeutics - expects cash, as of march 31, to be sufficient to fund capex needs in q1 2022.
FULC Ratings Summary
FULC Quant Ranking